دورية أكاديمية
أعرض في EDS

Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up.

التفاصيل البيبلوغرافية
العنوان: Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up.
المؤلفون: Finall A; Cellular Pathology, Swansea Bay University Health Board, Port Talbot, UK afinall@me.com.; Medical School, Swansea University, Swansea, UK., Davies G; Cellular Pathology, Swansea Bay University Health Board, Port Talbot, UK., Jones T; Cellular Pathology, Swansea Bay University Health Board, Port Talbot, UK., Emlyn G; Cellular Pathology, Betsi Cadwaladr University Health Board, Bangor, UK., Huey P; Cellular Pathology, Betsi Cadwaladr University Health Board, Bangor, UK., Mullard A; Oncology, Betsi Cadwaladr University Health Board, Bangor, UK.
المصدر: Journal of clinical pathology [J Clin Pathol] 2023 Jun; Vol. 76 (6), pp. 391-399. Date of Electronic Publication: 2022 Jan 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 0376601 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1472-4146 (Electronic) Linking ISSN: 00219746 NLM ISO Abbreviation: J Clin Pathol Subsets: MEDLINE
أسماء مطبوعة: Publication: London : BMJ Pub. Group
Original Publication: London : British Medical Association
مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/diagnosis , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/diagnosis , Lung Neoplasms*/genetics , Lung Neoplasms*/drug therapy, Humans ; Retrospective Studies ; Follow-Up Studies ; Mutation ; Polymerase Chain Reaction ; ErbB Receptors/genetics ; High-Throughput Nucleotide Sequencing ; United Kingdom
مستخلص: Aims: Somatic genetic testing in non-squamous, non-small cell lung carcinoma (NSCLC) patients is required to highlight subgroups eligible for a number of novel oncological therapies. This study aims to determine whether turnaround times for reporting epidermal growth factor receptors (EGFR) by next-generation sequencing (NGS) alone is sufficient to meet the needs of lung cancer patients.
Methods: We performed a retrospective case series with follow-up. Outcomes of EGFR testing (102 tests) in 96 patients by NGS were compared with a rapid, fully automated PCR-based platform (Idylla) in local histopathology laboratories.
Results: Turnaround time for reporting NGS was 17 calendar days. Reporting using the Idylla EGFR Mutation Test, by contrast, gave a potential turnaround time of 3.8 days from request to authorisation. Three-quarters of patients presenting with stage IV disease had a performance status of 0, 1, or 2 but 18% experienced rapid clinical deterioration (p<0.05). A third of these patients were deceased by the time NGS reports were available.
Conclusions: We discuss issues around integrating rapid PCR testing alongside NGS in multidisciplinary care pathways and strategies for mitigating against foreseeable difficulties. Dual testing for stage IV non-squamous, NSCLC patients has the potential to improve care and survival outcomes by providing access to the right test at the right time.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
فهرسة مساهمة: Keywords: genes; lung neoplasms; medical oncology; neoplasm; pathology; polymerase chain reaction; surgical
المشرفين على المادة: EC 2.7.10.1 (ErbB Receptors)
تواريخ الأحداث: Date Created: 20220119 Date Completed: 20230522 Latest Revision: 20230522
رمز التحديث: 20230522
DOI: 10.1136/jclinpath-2021-207987
PMID: 35042754
قاعدة البيانات: MEDLINE
الوصف
تدمد:1472-4146
DOI:10.1136/jclinpath-2021-207987